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Introduction
The prevalence of human immunodeficiency virus (HIV)-1-associated neurocognitive disorders (HAND) continues to rise in HIV-1 infected people despite widespread use of antiretroviral therapies (ART) (Letendre et al., 2007) . HAND parallels increases in patient life span (Boisse et al., 2008) , the emergence of resistant viral phenotypes, drug toxicities, incomplete ART blood brain barrier penetration and sustained mononuclear phagocyte (MP; blood borne macrophages and microglia) HIV-1 brain infection (Charpentier et al., 2004; Deeks et al., 2005; Roquebert et al., 2006; Tozser, 2001) . All have hampered drug successes. Sustained neuroinflammatory responses and the secretion of viral and cellular neurotoxins by immune competent and HIV-1 infected brain MP in the face of restricted viral growth now characterize HAND pathobiology (Buscemi et al., 2007; Dhillon et al., 2008; Herbein et al., 2008; Okamoto et al., 2005) . HIV-1 infected and activated brain MP secrete reactive oxygen species and pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β) and IL-8, which can affect neural function (Janelsins et al., 2008; Stone and Behan, 2007; Viviani et al., 2006; Xiong et al., 2003) . Of the putative cellular toxins, those linked to the arachidonic acid pathway are considered among the most significant in affecting cytotoxicities (Fang et al., 2008; Kwon et al., 2005; Sang et al., 2005) . Indeed, several of the leukotrienes; HETEs, prostaglandins and platelet activating factor (PAF) affect MP inflammatory responses seen in a broad range of systemic degenerative and nervous system disorders (Bate et al., 2006a,b; Ichiyama et al., 2009; Rey et al., 1998; Schuhmann et al., 2003; Smith et al., 2001) .
Of the metabolites of arachidonic acid, PAF has broad effects on innate immunity and HAND pathobiology (Del Sorbo et al., 2001 , 1999 Perry et al., 1998; Tong et al., 2001) . This includes PAF's abilities to affect MP chemotaxis (Del Sorbo et al., 1999) , neurotoxicity (Ryan et al., 2008) and cellular metabolism (Belanger et al., 2008) . HIV-1 replication is enhanced by PAF (Herbein and Khan, 2008; Herbein et al., 2008; Lima et al., 2006) . PAF leads to increased TNF-α MP secretion activating both the classical nuclear factor kappa beta (NF-κB) and mitogen activated protein kinase (MAPK) pathways resulting in IL-1, -6, -10 and TNF-α production (Kihara et al., 2005; Lee et al., 2005; Muller-Ladner et al., 2002) . TNF-α affects HIV-1 replication and as a result enhances the concentration of viral and cellular toxins including PAF (Sneddon et al., 2006) . Previous studies performed by Journal of Neuroimmunology 213 (2009) [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] 
